Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53-independent p21 induction by MELK inhibition

15 Jun 2017

Abstract excerpt

// Tatsuo Matsuda 1 , Taigo Kato 1 , Kazuma Kiyotani 1 , Yunus Emre Tarhan 1 , Vassiliki Saloura 1 , Suyoun Chung 2 , Koji Ueda 3 , Yusuke Nakamura 1,4 and Jae-Hyun Park 1 1 Department of Medicine, The University of Chicago, Chicago, IL, USA 2 OncoTherapy Science Inc., Kawasaki, Japan 3 Project for Realization of Personalized Cancer Medicine, Cancer Precision Medicine Center, Japanese Foundation for Cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cell death mechanisms and regulation
Share to FOXO transcription factor regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28938528
DOI: 10.18632/oncotarget.18488

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53-independent p21 induction by MELK inhibitionPMID 28938528Read ↗

Maternal Embryonic Leucine Zipper Kinase (MELK) in Cancer: Biological Functions, Therapeutic Potential, and ControversiesSemantic proximity Read ↗

Maternal Embryonic Leucine Zipper Kinase: Key Kinase for Stem Cell Phenotype in Glioma and Other CancersSemantic proximity Read ↗

MELK inhibition effectively suppresses growth of glioblastoma and cancer stem-like cells by blocking AKT and FOXM1 pathwaysSemantic proximity Read ↗

Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 MutationsSemantic proximity Read ↗

Polo-like kinase 2 targeting as novel strategy to sensitize mutant p53-expressing tumor cells to anticancer treatments.Semantic proximity Read ↗

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinomaSemantic proximity Read ↗

Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancerSemantic proximity Read ↗

STK3 kinase activation inhibits tumor proliferation through FOXO1-TP53INP1/P21 pathway in esophageal squamous cell carcinomaSemantic proximity Read ↗

Recent Advances of Wee1 Inhibitors and Statins in Gynecologic Cancers with p53 MutationsSemantic proximity Read ↗

MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence.Semantic proximity Read ↗

Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cellsSemantic proximity Read ↗

Regulation of ULK1 by WTAP/IGF2BP3 axis enhances mitophagy and progression in epithelial ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.